TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris Corporate
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III
(Thrombate III)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
United States
Home
About Talecris US
Our Products
Our Services
Media Center
Careers
Media Center
Press Releases
Request Updates from Media Center
Media Center
Press Releases
To see all our press releases, visit the archive on the Talecris corporate Web site.
July 24, 2008
Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission
June 16, 2008
Talecris Biotherapeutics, Inc. Provides Business Update
May 22, 2008
Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation
May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
May 08, 2008
FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP
View press release archive on the Talecris corporate site.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2008 Talecris Biotherapeutics